A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study
- PMID: 35767079
- DOI: 10.1007/s10147-022-02204-x
A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study
Abstract
Background: Late recurrence of renal cell carcinoma (RCC) is observed in some postoperative patients. In addition, some of these patients are lost to long-term postoperative follow-up. We reviewed the treatment results and prognosis of postoperative patients with RCC at Chiba University Hospital, with the aim of clarifying the proportion and background of patients lost to follow-up.
Methods: This retrospective study included 1176 RCC patients who underwent radical or/and partial nephrectomy. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and lost follow-up free survival (LFFS) were evaluated and the risk factors for LFFS identified.
Results: The median RFS for stage II and II cases was 188.3 and 104.0 months, respectively. Even in stage I, recurrence was observed in about 20% of patients 20 years after surgery. The Kaplan-Meier curve for LFFS showed a linear descent over time, with 50% of patients lost to follow-up within 25 years. Older age (≥ 62 years), histological type (clear cell RCC), and no recurrence were significant risk factors for lost follow-up.
Conclusions: Long-term follow-up is necessary after RCC surgery because late recurrence cases are not uncommon. We believe that lifelong follow-up with imaging studies is recommended for postoperative RCC patients. Early detection of recurrence in postoperative patients is a very important issue, and it may be worthwhile for improving the prognosis of postoperative patients to focus on patients lost to follow-up who may have been overlooked.
Keywords: Lost follow-up free survival; Nephrectomy; Postoperative; Recurrence; Renal cell carcinoma.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
References
-
- Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- Marumo K, Kanayama H, Miyao N et al (2007) Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol 14(6):479–482. https://doi.org/10.1111/j.1442-2042.2007.01739.x - DOI - PubMed
-
- Dabestani S, Marconi L, Kuusk T et al (2018) Follow-up after curative treatment of localised renal cell carcinoma. World J Urol 36(12):1953–1959. https://doi.org/10.1007/s00345-018-2338-z - DOI - PubMed
-
- Frees SK, Kamal MM, Nestler S et al (2019) Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancy. Int J Urol 26(3):385–390. https://doi.org/10.1111/iju.13882 - DOI - PubMed
-
- Stewart-Merrill SB, Thompson RH, Boorjian SA et al (2015) Oncologic surveillance after surgical resection for renal cell carcinoma: a novel risk-based approach. J Clin Oncol 33(35):4151–4157. https://doi.org/10.1200/jco.2015.61.8009 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
